anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a model animal with the overexpression of regucalcin which is inherently expressed in the liver or the like of higher animals, showing bone disease conditions typified by osteoporosis.  <P>SOLUTION: Regucalcin cDNAs are cloned from a rat liver cDNA library and a full-length cDNA encoding the regucalcin protein is isolated. The ORE is excised from the rat regucalcin full-length cDNA and transferred into an expression vector (pCXN2). Then, the gene expression vector is microinjected into the male pronucleus of a fertilized rat ovum. The fertilized ovum is transplanted into the uterine tube of a host rat, and a rat infant is developed. From this newborn child, a homozygous rat is constructed. The transgenic rat exhibits remarkable morphological and biochemical bone disease conditions, and body weight gain is significantly inhibited.  <P>COPYRIGHT: (C)2003,JPO
Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the "standard care" treatment.
INTRODUCTION: High-grade intraepithelial lesions (CIN 2/3) are considered precursor lesions of cervical cancer, and its treatment involves destructive or excisional methods. Some studies have proven the efficacy of the immunomodulator imiquimod as a topical treatment for CIN 2/3 lesions. Imiquimod activates the innate immune response through dendritic cells, monocytes and macrophages, in addition to modulating the response pattern of T lymphocytes. Thus, the characterization of the immune response in the treatment with imiquimod in lesions caused by oncogenic HPV, may benefit women in a way that it is possible to measure the response of each patient, improving the understanding of its mechanism of action, directly impacting the efficacy and adverse events. caused by the drug. OBJECTIVES: To identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. MATERIALS AND METHODS: It will be included 90 patients, 60 with high-risk HPV, diagnosed with CIN 3 and 30 patients with negative cytology and HPV. Patients will be divided into 3 groups: 1) patients with CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week; 2) patients with CIN 3 who will undergo standard treatment with Transformation Zone Excision (EZT); 3) patients with negative cytology and HPV. Blood and cervicovaginal lavage will be collected for immunophenotypic analysis (flow cytometry), quantification of immunological mediators (Cytometric Bead Array) and evaluation of the microbiome (MiniION). The results obtained will be correlated with the clinical and pathological data of the patients.
Controlled-release oxycodone (CRO) was used in this study. The patients kept a daily record of the intensity of pain. CRO is effective for 12 h, so that the patient takes it only twice a day.The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 20 mg. Thus, we began at a dose of 20 mg by default. When the pain worsened, the dose was quickly titrated.When a patient who was suffering from moderate pain in the mouth, pharynx, or larynx consented to take oxycodone, oxycodone was begun at the level of moderate pain. We called this the mild group. In contrast, those patients who did not ask for oxycodone until the pain reached a severe level were called the severe group. Because all patients agreed to use an opioid at some point, the patients were classified into two groups, moderate and severe, according to when the opioid was introduced.

Total dose of oxycodone was defined as the total dose of oxycodone taking during the treatment of chemoradiotherapy. Pain Remission Rate was defined as pain remission after 24h from the start of opioid administration.Evaluating quality of life were conducted once every two weeks.We also evaluated the weight loss as parameters for food intake once a week,until the radiotherapy.All statistical analyses were performed using SPSS software.
Participants in this group will receive a dietary information packet via mail or email, which will consist of the sections of the DGA relevant to 12-24 month old children (Included as a supplemental document, "Standard dietary guidance"). This dietary guidance will also be provided at the 18- and 24-month visits. Please note that participants in this arm will receive their personalized diet information at the conclusion of the study.
Through a large number of literature review and preliminary experiments, we summarized and found the following problems: a. The latest research on prevention of scar formation by botulinum toxin type A is only aimed at surgical wounds from the wound type, and there is no research on the scar prevention effect of trauma wounds. b. From the point of view of the study site, there is no study on the effect of scar prevention only on the head, neck, chest and other parts of the body. c. For the research results of botulinum toxin type A in the prevention of scarring, the current research focuses on the effectiveness of botulinum toxin type A at a certain concentration, and does not compare the effects of botulinum toxin type A at various concentrations.Therefore, in order to explore the "optimal concentration" of botulinum toxin type A to prevent scar formation; To explore the effect of botulinum toxin A on scar prevention of traumatic wounds and surgical incisions. To explore the effect of botulinum toxin A on scar prevention in other parts of the body in addition to effective prevention of head, neck and chest scar, We intend to focus on the effectiveness and "optimal concentration" of botulinum toxin type A to prevent scarring, to determine the effect of this means on scar prevention, to provide new ideas for botul
Patients who will start radiotherapy after breast cancer surgery will be evaluated prior to treatment. During the radiotherapy process, all of the patients will be included in the home exercise program, 5 days a week, 2 sessions a day, each exercise will be 10x2 repetitions. Exercise follow-up of the patients will be provided with weekly routine face-to-face checks. After an average of 6 weeks of radiotherapy, the initial evaluations will be repeated.
Homeless youth experience many daily stressors, including hunger, poor sleep, harassment, and violence. Many also have been victims of child abuse and/or neglect, witnessed family and/or community violence, and/or lived in foster care prior to leaving the home setting - exposures labeled as adverse childhood experiences known to increase the risk for poor physical and mental health. Because homeless youth are often disconnected from families, friends and institutions (e.g. health care, schools, jobs), they are at greater risk for "toxic stress" resulting in impaired biological stress responses with high or low levels of the stress hormone, cortisol, and increased inflammation in the cells of the body. High levels of inflammation are associated with sickness behavior syndrome (e.g. fatigue), depression, and suicidal thoughts, which may lead youth to engage in risky behaviors (e.g. substance use, HIV risk behaviors) in an attempt to reduce symptoms. However, few studies have collected biological measures of stress among homeless youth despite prior research linking exposure to violence and trauma to impaired biological stress responses in the general population. Because homeless youth experience a greater number of adverse exposures and with higher levels of severity on a daily basis and across their lifetime than youth in the general population, our lack of understanding of the biological impact that these exposures have on homeless youths' physical and mental health in the short-term as well as across their life span limits understanding of which youth are most vulnerable to poor outcomes. This study's purpose is to test the feasibility of collecting acute and chronic stress response biomarkers in homeless youth for use with future planned research. The study will also assess changes in acute stress (biological and psychological) via salivary cortisol and alpha amylase levels as well as survey measures of self-reported anxiety in response to either (a) a free online guided mindfulness meditation available at (https://www.uclahealth.org/marc/mindful-meditations); (b) a guided mindfulness meditation via virtual reality (https://guidedmeditationvr.com/) or (c) a virtual reality platform of historic photographs and written narratives (https://lookingglassvr.com/). Participants will also complete an interviewer administered survey to measure sociodemographic factors, mental and physical health status, substance use, and medication use and provide a hair sample to measure cortisol.
Participants will receive foods containing 20 g of soy flour to be consumed everyday for one week. If they tolerate the dose, they will receive the next dose without any wash-out period.
OBJECTIVE: The objective of this study was to investigate the perioperative management and outcomes of patients with a prior history of successful transplantation undergoing spine surgery.
METHODS: We searched Medline, Embase, and Cochrane Central Register of Controlled Trials for matching reports in July 2021. We included case reports, cohort studies, and retrospective analyses, including terms for various transplant types and an exhaustive list of key words for various forms of spine surgery.
RESULTS: We included 45 studies consisting of 34 case reports (published 1982-2021), 3 cohort analyses (published 2005-2006), and 8 retrospective analyses (published 2006-2020). The total number of patients included in the case reports, cohort studies, and retrospective analysis was 35, 48, and 9695, respectively. The mean 1-year mortality rate from retrospective analyses was 4.6% ± 1.93%, while the prevalence of perioperative complications was 24%. Cohort studies demonstrated an 8.5% ± 12.03% 30-day readmission rate. The most common procedure performed was laminectomy (38.9%) among the case reports. Mortality after spine surgery was noted for 4 of 35 case report patients (11.4%).
CONCLUSIONS: This is the first systematic scoping review examining the population of transplant patients with subsequent unrelated spine surgery. There is significant heterogeneity in the outcomes of post-transplant spine surgery patients. Given the inherent complexity of managing this group and elevated mortality and complications compared to the general spine surgery population, further investigation into their clinical care is warranted.
A cap for a medication container includes a housing with a top portion and a bottom portion. The top and bottom portions together define a cavity therebetween. A sliding plate is disposed in the cavity adjacent the bottom portion. A microcontroller with a contact sensor is disposed in the cavity between the top portion and the sliding plate. The sliding plate is configured to slide toward and activate the contact sensor where the cap is secured to the medication container in a closed state. The sliding plate is also configured to slide away from and not activate the contact sensor where the cap is removed from the medication container in an open state.
Nabumetone is a naphthylalkanone designated chemically as 4-(6-methoxy-2-naphthalenyl)-2-butanone. It has the following structure:

C15H16O2 M.W. 228.3

Nabumetone is a white to off-white crystalline substance. It is nonacidic and practically insoluble in water, but soluble in alcohol and most organic solvents. It has an n-octanol:phosphate buffer partition coefficient of 2,400 at pH 7.4.

Each tablet, for oral administration, contains either 500 mg, 750 mg, or 1000 mg of nabumetone. In addition, each tablet contains the following inactive ingredients: povidone, croscarmellose, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide. The coating contains hydroxypropyl cellulose and hypromellose.
PURPOSE: To provide the novel medical compsn. for diabetic nephropathy treatment which decreases albumin urine without changing the filtration rate of glomerculus and has low toxicity. CONSTITUTION: This medicinal compsn. contains the sulodexide (chemical name: glucurono-2-amino-2-deoxyglucansulfate) which is the naturally derived glycosaminoglycan extracted from the intestinal mucosa of mammals having the sulfation degree and anti-coagulation activity lower than those of heparin. This compsn. is preferably formed in the form to allow the medication of the sulodexide at a dose of 41.6 to 124 mg per day. The compd. is conveniently used in all forms medicatable by an oral route, subcutaneous route, muscular route or venous route.
The strategy to activate thermogenic adipocytes has therapeutic potential to overcome obesity as they dissipate surplus energy as heat through various mechanisms. NG,NG-dimethylarginine dimethylaminohydrolases (DDAHs) are enzymes involved in the nitric oxide-protein kinase G signaling axis which increases thermogenic gene expression. However, the role of DDAHs in thermogenic adipocytes has not been elucidated. The adipocyte-specific Ddah1 knockout mice are generated by crossing Ddah1fl/fl mice with adiponectin Cre recombinase mice. Adipocyte-specific DDAH1 overexpressing mice are generated using adeno-associated virus-double-floxed inverse open reading frame (AAV-DIO) system. These mice are analyzed under basal, cold exposure, or high-fat diet (HFD) conditions. Primary inguinal white adipose tissue cells from adipocyte-specific Ddah1 knockout mice expressed comparable amounts of Ucp1 mRNA. Adipocyte-specific DDAH1 overexpressing mice do not exhibit enhanced activation of thermogenic adipocytes. In addition, when these mice are exposed to cold environment or fed an HFD, their body temperature/weight and thermogenesis-related gene and protein expressions are unchanged. These findings indicate that DDAH1 does not play a role in either cold- or diet-induced thermogenesis. Therefore, adipocyte targeting DDAH1 gene therapy for the treatment of obesity is unlikely to be effective.
The invention provides a cigarette additive, belonging to the technical field of medicine, which is prepared by screening hundreds of traditional Chinese medicines with health care and treatment effects on human bodies from tens of thousands of traditional Chinese medicines according to the theories of Chinese and western medicines, and finally determining a plurality of types of compatibility through repeated research and experiments for many years, wherein the formula of the cigarette additive is as follows: 5-6g of schisandra chinensis, 5-6g of cortex acanthopanacis, 5-6g of tea, 5-6g of dahurian rhododendron leaf, 3-4g of aster, 3-4g of walnut branches and 3-4g of liquorice, decocting the above medicinal materials, spraying tobacco shreds on the decoction, and then preparing the cigarette. The additive has the following advantages: (1) to excite the spirit of people. (2) Improving intelligence of human. (3) Has antiinflammatory, antiasthmatic, antitussive, and expectorant effects. (4) Has anticancer effect. The method has the characteristics of scientificity, novelty, applicability and economy.
PURPOSE:To purify an antigen or antibody by the affinity chromatography using a carrier bonded with an antigen or antibody. CONSTITUTION:A solution containing an antigen (e.g. interferon) or an antibody is made to contact with an insoluble carrier (e.g. callulose, agarose, crosslinked dextran, polyacrylamide, porous glass, etc.) bonded with the antibody or antigen corresponding to the above antigen or antibody, to effect the adsorption of the antigen or antibody from the solution. The adsorption of the antigen or antibody from the solution. The adsorbed antigen or antibody is recovered with an acidic buffer solution containing lysolecithin, to obtain an antigen or antibody having high safety, in high yield and purity. EFFECT:The lysolecithin has a specific interferon-recovering effect by the action of surfactant. Since the lysolecithin is nontoxic, the interferon prepared by the above process can be administered safely to human body. The agent has excellent stability.
BACKGROUND AND AIMS: Most experimental studies of allograft vasculopathy (AV) have relied on transplantation between major histocompatibility complex-mismatched inbred mouse strains, but this leads to the complete eradication of donor smooth muscle cells (SMCs) and lesions formed by recipient cells. This is unlike human AV which is thought to form mainly by donor SMCs. Here, we studied sources of neointimal cells in a minor histocompatibility antigen-mismatched AV model by combining male-to-female orthotopic carotid transplantations and lineage tracing by SMC-specific expression of fluorescent proteins.
METHODS: To track SMC-derived cells in allograft vasculopathy, we used male donor mice with SMC-restricted Cre recombination of the mT/mG reporter transgene, which switches expression of membrane-bound red fluorescent protein (RFP) to green fluorescent protein (GFP), or the stochastically recombining Confetti reporter transgene, which yields a mosaic expression of four fluorescent proteins. Donor carotid segments were harvested and orthotopically allografted to female recipients that were wildtype or had non-recombined reporter transgenes. Inhibition of T cell responses by CTLA4Ig was used in some experiments. Sections of lesions harvested after 4 weeks were analyzed by fluorescence microscopy.
RESULTS: Donor-derived SMCs survived and gave rise to part of the neointimal cells in experiments where carotid segments from recombined mT/mG male mice were transplanted into wild-type or non-recombined mT/mG female mice. Sex-mismatched transplants developed significant lesions, increasing the intimal and medial area 4.6-fold (p = 0.038) and 2.0-fold (p = 0.024) compared to sex- and fluorescence-matched controls, respectively. Interestingly, sex-matched fluorescence-positive transplants developed intimal lesions in 50% of fluorescence-naïve recipient controls. To study the clonal structure of the neointimal donor-derived SMC lineage cells, we then transplanted male carotids with heterozygous or homozygous recombined Confetti transgenes into female recipients. These transplants developed lesions with few surviving donor SMCs, indicating that expression of the Confetti reporter increased rejection and donor-specific SMC death. Some of the few remaining donor SMCs underwent clonal expansion. CTLA4Ig administration at the time of surgery did not improve SMC survival in mT/mG or Confetti transplants.
CONCLUSION: Male-to-female transplant models feature donor-derived SMCs, some of which undergo clonal expansion, but immune rejection to fluorescence reporters appears to bias results in lineage tracing models. Overcoming these challenges with alternative reporter transgenes or tolerant recipients is necessary to study the mechanisms by which donor SMCs contribute to allograft vasculopathy.
PURPOSE: To provide the composition which contains a benzomorpholine derivative as an active ingredient and has a decoloring effect and accordingly, is useful for bleaching skin or treating skin spots due to pigment deposition. CONSTITUTION: This composition contains a compound represented by the formula (wherein: R1 is H or a C1 to C4 alkyl group; and R2 is OH at the 6- or 7-position), e.g. 6-hydroxybenzomorpholine, as an active ingredient in a 0.01 to 10 wt.% concn. based on the total weight of the composition and is prepared by appropriately blending this compound with other components such as lubricant, surfactant, keratolytic agent, anti-inflammatory agent, comlexing agent, oxidation inhibitor, preservative agent and/or aroma, and forming the resulting blend into a form such as lotion, cream, emulsion, gel, pack, microspheres or dispersion of vesicles. As for the amount of application, for example, the composition in the form of cream is applied to skin in a frequency of 1 to 2 times per day and in a 0.5 to 3 mg/cm<2> amount per unit skin area, for each application.  This composition shows a more excellent decoloring effect than that of hydroquinone.
This invention provides a cell line of M2C macrophage and its applications. The cell line is derived from monocytes isolated from bone marrows and peripheral blood. The monocytes were differentiated into M2 macrophage by macrophage colony-stimulating factor (M-CSF), and then the polarization of M2C macrophage was induced by baicalin. The MERTK, PTX3, and PD-L1 expression level of the M2C macrophage are high and promote phagocytosis. Hence it can be applied to cell therapy or biological agents of immune regulation. Also, the macrophage-conditioned medium and wound dressing prepared on the M2C cell have the effects of enhancing fibroblast proliferation and angiogenesis, which can improve wound healing in medical use, and can be applied to skin care product for skin repair and rejuvenation.
PURPOSE:To provide the titled composition containing a vegetable proteinase  and sodium chloride, and storable in air for a long period without causing degradation and putrefaction. CONSTITUTION:The titled composition contains 0.1-1.0wt%vegetable proteinase (e.g. papain, bromelin, ficin, etc.) and 8-15wt% (preferably about 10wt%) sodium chloride. The presence of vegetable proteinase in the bath liquid composition is effective to decompose the dirt in the bath, remove the ill odor, and improve the clarity of water in the bath tub, and furthermore, it is expected to exhibit the cleaning effect to the skin. The addition of sodium chloride to the composition enables the stable storage of the bath liquid composition containing the vegetable proteinase, in air for a long period.
The present invention describes methods for identification of molecules expressed at a different level on the cell surface of cancer cells compared to non-malignant cells and methods of identification of cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer. The invention furthermore describes targeting complexes targeted to cell surface molecules identified by the methods of the invention. In embodiments of the invention said targeting complexes comprise the promoters identified by the methods of the invention. In addition the invention describes methods of identifying binding partners for the cell surface molecules and the binding partners per se. Methods of treatment using the targeting complexes and uses of the targeting complexes for the preparation of a medicament are also disclosed by the invention. Furthermore, the invention describes uses of the cell surface molecules or fragments thereof for preparation of vaccines.
Additionally to standard post-operative regimen, patients who will be undergoing their first PKP surgery and who meet all inclusion and no exclusion criteria will be included in the experimental group. These patients will administer topical infliximab four times per day for 3 months.
PROBLEM TO BE SOLVED: To obtain an oral solid preparation capable of improving the remedying effect of symptoms such as gastroxynsis, improved in uncomfortable flavor, easy to take, and useful as a therapeutic agent for e.g. gastritis, by including sofalcone, arm alkaline matter, menthol or the like. SOLUTION: This oral solid preparation is obtained by including (A) sofalcone, (B) a surfactant such as polysorbate 80, (C) an alkaline matter, pref. such as sodium bicarbonate or aluminum hydroxide and (D) pref. 0.01-0.6 wt.%, more pref. 0.05-0.2 wt.%, based on the whole preparation, of one or two kinds of menthol pref. selected from L-menthol and DL-menthol. The dosage form of this preparation is pref. powder, or (fine) granules.